Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 15/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259595 | 0.79 | EGLN2 (0.49) | ALDH1A1EGLN2ENPP1HTT | |
| SCHEMBL138355 | 0.76 | ALDH1A1 (0.44) | ALDH1A1EGLN2ENPP1HTT | |
| SCHEMBL23055294 | 0.73 | ALDH1A1 (0.42) | ALDH1A1EGLN2 | |
| SCHEMBL25347932 | 0.72 | EGLN2 (0.40) | ALDH1A1EGLN2 | |
| SCHEMBL259718 | 0.71 | EGLN2 (0.38) | ALDH1A1EGLN2ENPP1 | |
| SCHEMBL25124572 | 0.69 | EGLN2 (0.54) | ALDH1A1EGLN2ENPP1 | |
| SCHEMBL23998384 | 0.67 | ALDH1A1 (0.37) | ALDH1A1EGLN2 | |
| SCHEMBL6117758 | 0.67 | EGLN2 (0.58) | EGLN2 | |
| SCHEMBL26857578 | 0.65 | PIK3CG (0.49) | ALDH1A1NPC1RAB9A | |
| SCHEMBL64680 | 0.65 | ALDH1A1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010947-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115996929-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4146654-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | Adorx therapeutics Limited (GB) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021224636-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | AdoRx Therapeutics Limited (GB) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021224636-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | AdoRx Therapeutics Limited (GB) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 1348/4885EGLN2 1526/4885ENPP1 640/4885 |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | ALDH1A1 431/4885EGLN2 2509/4885ENPP1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.